Pain News and Research RSS Feed - Pain News and Research

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain. [More]
Surgeon explains who needs screening for abdominal aortic aneurysms

Surgeon explains who needs screening for abdominal aortic aneurysms

Bulges in body's major blood vessel can cause potentially lethal ruptures, blood clots. An abdominal aortic aneurysm is a potentially life-threatening condition: If the body's major blood vessel ruptures, it can prove deadly. [More]
Once-a-day pill for patients experiencing opioid-induced constipation

Once-a-day pill for patients experiencing opioid-induced constipation

Opioids - strong morphine-based painkillers - are widely prescribed to patients experiencing chronic severe pain. While these drugs are very effective for treating and managing pain, they have one particularly bothersome side effect: constipation. [More]
Women with history of pregnancy loss are at higher risk for cardiovascular disease later

Women with history of pregnancy loss are at higher risk for cardiovascular disease later

The Annals of Family Medicine today published an article detailing research showing that women with a history of pregnancy loss are at higher risk for cardiovascular disease later in adulthood than other women, work completed by physicians in the Center for Primary Care and Prevention (CPCP) at Memorial Hospital of Rhode Island. [More]
More insurers want you to see a doctor virtually

More insurers want you to see a doctor virtually

Insurers like WellPoint and Aetna are offering patients the option of e-visits with doctors as a way to cut costs, but some see problems with that, reports Bloomberg. Other media outlets explore the controversy over Sovaldi, an expensive new drug for hepatitis C. [More]
Thirteen scientists receive grant to identify new treatments, cure for psoriasis

Thirteen scientists receive grant to identify new treatments, cure for psoriasis

Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis—an autoimmune disease that appears on the skin, affecting 7.5 million Americans—and psoriatic arthritis—an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis. [More]
Virobay announces closing of expanded Series B second tranche financing

Virobay announces closing of expanded Series B second tranche financing

Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million. [More]
Anti-clotting treatment not needed for all kids who undergo spine operations

Anti-clotting treatment not needed for all kids who undergo spine operations

Blood clots occur so rarely in children undergoing spine operations that most patients require nothing more than vigilant monitoring after surgery and should be spared risky and costly anti-clotting medications, according to a new Johns Hopkins Children's Center study. [More]
Novagant releases GoldenCBD oil including capsules and liquids

Novagant releases GoldenCBD oil including capsules and liquids

Novagant Corp. is pleased to announce that in this month of July it will release its GoldenCBD™ oil that will be available in several forms, including capsules and liquids. It will be the answer for those Medical Cannabis Patients living outside Washington and Colorado. [More]
Hydroxychloroquine treatment not effective for primary Sjögren syndrome

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

Among patients with the systemic autoimmune disease primary Sjögren syndrome, use of hydroxychloroquine, the most frequently prescribed treatment for the disorder, did not improve symptoms during 24 weeks of treatment compared with placebo, according to a study in the July 16 issue of JAMA. [More]
Telecare intervention leads to improvement in chronic musculoskeletal pain

Telecare intervention leads to improvement in chronic musculoskeletal pain

A telephone-delivered intervention, which included automated symptom monitoring, produced clinically meaningful improvements in chronic musculoskeletal pain compared to usual care, according to a study in the July 16 issue of JAMA. [More]
LUTS questionnaire validated in Japanese population

LUTS questionnaire validated in Japanese population

The Core Lower Urinary Symptom Score questionnaire has been validated for use in Japanese patients and may be useful as a screening tool in both clinical or research settings, researchers report. [More]
Embolisation of abnormal neovessels relieves osteoarthritic knee pain

Embolisation of abnormal neovessels relieves osteoarthritic knee pain

Transcatheter arterial embolisation relieves knee pain in patients with moderate osteoarthritis who are resistant to pharmacological pain management, research suggests. [More]
Japanese SF-MPQ valid for neuropathic and non-neuropathic pain

Japanese SF-MPQ valid for neuropathic and non-neuropathic pain

Researchers have developed a Japanese translated version of the Short-Form McGill Pain Questionnaire-2 that shows good reliability and validity for discriminating between chronic neuropathic and non-neuropathic pain. [More]
Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Firstly, paracetamol has been the first-line recommended treatment for osteoarthritis pain for very many years and, secondly, it is readily available over the counter and can be bought in relatively large quantities. [More]

VA struggles with sharp rise in disability claims

Also in the news, efforts continue to unravel the scandals related to delayed care at veterans' facilities. [More]
Study: 27% of hospice patients still take antibiotics in the final week of their life

Study: 27% of hospice patients still take antibiotics in the final week of their life

New research suggests that use of antibiotics is still prevalent among terminal patients who have chosen hospice care as an end-of-life option, despite little evidence that the medications improve symptoms or quality of life, and sometimes may cause unwanted side effects. [More]
Researchers create combination drug that controls both tumor growth and metastasis

Researchers create combination drug that controls both tumor growth and metastasis

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread. [More]
First Edition: July 14, 2014

First Edition: July 14, 2014

Today's headlines include coverage of Medicare, the health law and veterans' care policy issues as well as reports from the campaign trail. [More]
Mylan enters into definitive agreement to acquire Abbott's branded generics pharmaceuticals business

Mylan enters into definitive agreement to acquire Abbott's branded generics pharmaceuticals business

Mylan Inc. today announced that it has entered into a definitive agreement with Abbott whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business ("the Assets") in an all-stock transaction. [More]